Pharmacological cardioversion of atrial fibrillationa double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously

Europace

Volumn 13, Issue 8, 2011, Pages 1148-1156

  Rónaszki, Aladár ^a   Alings, Marco ^b   Egstrup, Kenneth ^c   Gaciong, Zbigniew ^d   Hranai, Marián ^e   Király, Csaba ^e   Sereg, Matyas ^e   Figatowski, Włodzimierz ^f   Błondarov, Patrik ^g   Johansson, Susanne ^g   Frison, Lars ^g   Edvardsson, Nils ^g   Berggren, Anders ^g  

^a Peterfy Hospital   (Hungary)

^b AMPHIA HOSPITAL   (Netherlands)

^c Sygehus Fyn   (Denmark)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e Kardiocentrum Nitra Sro ^*  (Hungary)

^f Wojewódzki Szpital Zespolony Oddzia Kardiologii   (Poland)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

Antiarrhythmia agents; Atrial fibrillation; Torsade de pointes

Indexed keywords

ACENOCOUMAROL; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; AZD 1305; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; GLYCEROL NITRATE; ISOPRENALINE; MAGNESIUM; METOPROLOL; PERINDOPRIL; POTASSIUM; SPIRONOLACTONE; TRIMETAZIDINE; UNCLASSIFIED DRUG; VALSARTAN; WARFARIN;

ABDOMINAL WALL HEMATOMA; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ASTHMA; BODY TEMPERATURE DISORDER; BRADYCARDIA; CARDIAC ASTHMA; CARDIAC PATIENT; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE DURATION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DYSPNEA; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MUSCLE SPASM; PRESYNCOPE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SINUS BRADYCARDIA; SINUS RHYTHM; SUPRAVENTRICULAR TACHYCARDIA; TORSADE DES POINTES; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; URINARY TRACT INFECTION;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; AZABICYCLO COMPOUNDS; CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLACEBO EFFECT; TORSADES DE POINTES; TREATMENT OUTCOME;

EID: 80051727477     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur120     Document Type: Article

References (21)

1. Lip GY, Kakar P, Watson T. Atrial fibrillation-the growing epidemic. Heart 2007; 93:542-3.
2. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: Full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:651-745. (Pubitemid 44472247)
3. Waldo AL. A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: There remains an unmet need. Am Heart J 2006;151:771-8.
4. Andersson B, Abi-Gerges N, Carlsson L. The combined ion channel blocker AZD1305 attenuates late Na current and IKr-induced action potential prolongation and repolarisation instability. Europace 2010;12:1003-10.
5. Carlsson L, Andersson B, Linhardt G, Lö fberg L. Assessment of the ion channelblocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo. J Cardiovasc Pharmacol 2009;54:82-9.
6. Persson F, Carlsson L, Duker G, Jacobson I. Blocking characteristics of hERG, hNav1. 5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009. J Cardiovasc Electrophysiol 2005;16:329-41. (Pubitemid 40404601)
7. Persson F, Carlsson L, Duker G, Jacobson I. Blocking characteristics of hKv1. 5 and hKv4. 3/hKChIP2. 2 after administration of the novel antiarrhythmic compound AZD7009. J Cardiovasc Pharmacol 2005;46:7-17. (Pubitemid 40917773)
8. Crijns HJ, Van Gelder IC, Walfridsson H, Kulakowski P, Ronaszeki A Dedek V et al. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm 2006;3: 1321-31. (Pubitemid 44636926)
9. Edvardsson N, Walfridsson H, Aass H, Orning O, Rossvoll O, Kenneback G et al. Predominant effects on atrial versus ventricular refractoriness in man by the novel antiarrhythmic agent AZD7009 (Abstract P3047). Eur Heart J 2005;26:506.
10. Geller JC, Egstrup K, Kulakowski P, Rosenqvist M, Jansson MA, Berggren A et al. Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. J Clin Pharmacol 2009;49:312-22.
11. Burashnikov A, Zygmunt AC, Di Diego JM, Linhardt G, Carlsson L, Antzelevitch C. AZD1305 exerts atrial-predominant electrophysiological actions and is effective in suppressing and inhibiting reinduction of atrial fibrillation in the dog. J Cardiovasc Pharmacol 2010;56:80-90.
12. Sicouri S, Carlsson L, Antzelevitch C. Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves. J Pharmacol Exp Ther 2010;334:255-9.
13. Toivonen L, Raatikainen P, Walfridsson H, Englund A, Hegbom F, Anfinsen OG et al. A randomized, invasive cardiac electrophysiology study of the combined ion channel blocker AZD1305 in patients after catheter ablation of atrial flutter. J Cardiovasc Pharmacol 2010;56:300-8.
14. Persson F, Andersson B, Duker G, Jacobson I, Carlsson L. Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre. Eur J Pharmacol 2007;558:133-43. (Pubitemid 46350691)
15. Falk R, Pollak A, Singh S, Friedrich T, Intravenous Dofetilide Investigators. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol 1997;29:385-90. (Pubitemid 27059970)
16. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: The symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000;102: 2385-90.
17. Borgeat A, Goy JJ, Maendly R, Kaufmann U, Grbic M, Sigwart U. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986;58: 496-8. (Pubitemid 16052680)
18. Nichol G, McAlister F, Pham B, Laupacis A, Shea B, Green M et al. Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart 2002;87:535-43. (Pubitemid 34547976)
19. McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: Review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003;139:1018-33. (Pubitemid 37531534)
20. Ehrlich JR, Nattel S. Atrial-selective pharmacological therapy for atrial fibrillation: Hype or hope? Curr Opin Cardiol 2009;24:50-5.
21. Burashnikov A, Antzelevitch C. New developments in atrial antiarrhythmic drug therapy. Nat Rev Cardiol 2010;7:139-48.